Beyond the Guidelines: Perspectives on the Role of PARP
Inhibition in the Management of Ovarian Cancer — Interview with Dr
Lheureux on the following topic:
Overall survival data with maintenance olaparib for
platinum-sensitive recurrent OC with germline BRCA mutation from
the Phase III SOLO-2 trial; optimal integration of PARP inhibitors
in the treatment of recurrent disease (00:00)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.